Enhancing clinical research quality and safety through specialized nursing
We are developing an oncology trial, 28-day cycle, with study drug administered on day 1-7 (self-administered oral drug) and day 8 infusion.
Would you typically perform drug accountability (return of IP) on day 8 of the 28 day cycle (next visit)? Or at the end of the 28-day cycle (day 1, prior to next cycle dispensed)?
I am interested to learn from other research nurses in USA/Canada/Europe/Asia- when performing drug accountability, what is your local institutional practice or preference?
We have an SOP for oral drug accountability: https://ccrod.cancer.gov/confluence/download/attachments/73203825/PM-8%20v4.0%20Oral%20Drug%20Accountability_06.2020_signed.pdf?version=1&modificationDate=1593177259583&api=v2. Unfortunately, we don't address this, but typically it would be on a cycle per cycle basis.
International Association of Clinical Research Nurses
PO Box 7Mullica Hill, NJ 08062, USA(609) 519-9689 (Phone)firstname.lastname@example.org